EAP1 regulation of GnRH promoter activity is important for human pubertal timing.
Adolescent
Adult
Animals
Child
Female
Gene Expression Regulation
/ genetics
Gonadotropin-Releasing Hormone
/ genetics
Humans
Hypothalamus
/ metabolism
Male
Mice
Middle Aged
Neurons
/ metabolism
Promoter Regions, Genetic
/ genetics
Puberty
/ genetics
Puberty, Delayed
/ genetics
RNA, Messenger
/ genetics
Securin
/ genetics
Sexual Maturation
/ genetics
Trans-Activators
/ genetics
Transcription Factors
/ genetics
Exome Sequencing
Young Adult
Journal
Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958
Informations de publication
Date de publication:
15 04 2019
15 04 2019
Historique:
received:
19
11
2018
revised:
21
12
2018
accepted:
24
12
2018
pubmed:
5
1
2019
medline:
2
7
2019
entrez:
5
1
2019
Statut:
ppublish
Résumé
The initiation of puberty is orchestrated by an augmentation of gonadotropin-releasing hormone (GnRH) secretion from a few thousand hypothalamic neurons. Recent findings have indicated that the neuroendocrine control of puberty may be regulated by a hierarchically organized network of transcriptional factors acting upstream of GnRH. These include enhanced at puberty 1 (EAP1), which contributes to the initiation of female puberty through transactivation of the GnRH promoter. However, no EAP1 mutations have been found in humans with disorders of pubertal timing. We performed whole-exome sequencing in 67 probands and 93 relatives from a large cohort of familial self-limited delayed puberty (DP). Variants were analyzed for rare, potentially pathogenic variants enriched in case versus controls and relevant to the biological control of puberty. We identified one in-frame deletion (Ala221del) and one rare missense variant (Asn770His) in EAP1 in two unrelated families; these variants were highly conserved and potentially pathogenic. Expression studies revealed Eap1 mRNA abundance in peri-pubertal mouse hypothalamus. EAP1 binding to the GnRH1 promoter increased in monkey hypothalamus at the onset of puberty as determined by chromatin immunoprecipitation. Using a luciferase reporter assay, EAP1 mutants showed a reduced ability to trans-activate the GnRH promoter compared to wild-type EAP1, due to reduced protein levels caused by the Ala221del mutation and subcellular mislocation caused by the Asn770His mutation, as revealed by western blot and immunofluorescence, respectively. In conclusion, we have identified the first EAP1 mutations leading to reduced GnRH transcriptional activity resulting in a phenotype of self-limited DP.
Identifiants
pubmed: 30608578
pii: 5272618
doi: 10.1093/hmg/ddy451
pmc: PMC6452208
doi:
Substances chimiques
RNA, Messenger
0
Securin
0
Trans-Activators
0
Transcription Factors
0
pituitary tumor-transforming protein 1, human
0
Gonadotropin-Releasing Hormone
33515-09-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1357-1368Subventions
Organisme : NIH HHS
ID : P51 OD011092
Pays : United States
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/L002671/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 105519/Z/14/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 102745
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : R01 HD084542
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press.
Références
J Clin Endocrinol Metab. 2002 Dec;87(12):5581-6
pubmed: 12466356
Neuroendocrinology. 2018;106(3):283-291
pubmed: 28926843
Nat Protoc. 2015 Jun;10(6):845-58
pubmed: 25950237
Paediatr Perinat Epidemiol. 2011 May;25(3):306-11
pubmed: 21470270
Sci Rep. 2015 Jun 18;5:11208
pubmed: 26084728
Brain Res. 2010 Dec 10;1364:164-74
pubmed: 20851111
Eur J Endocrinol. 1998 Sep;139(3):271-5
pubmed: 9758435
Am J Hum Genet. 2018 Sep 6;103(3):456
pubmed: 30193138
Front Neuroendocrinol. 2015 Jul;38:73-88
pubmed: 25913220
Biochem Biophys Res Commun. 2000 Nov 30;278(3):766-74
pubmed: 11095982
Endocrinology. 2012 Jan;153(1):350-61
pubmed: 22128022
Endocrinology. 2009 Apr;150(4):1870-8
pubmed: 19022886
Endocrinology. 1989 Jul;125(1):92-9
pubmed: 2661213
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Mol Cell Endocrinol. 2011 Aug 6;342(1-2):8-19
pubmed: 21672609
Behav Brain Res. 2001 Nov 1;125(1-2):279-84
pubmed: 11682119
Arq Bras Endocrinol Metabol. 2012 Dec;56(9):646-52
pubmed: 23329188
N Engl J Med. 2012 Feb 2;366(5):443-53
pubmed: 22296078
Pediatrics. 2006 Aug;118(2):e391-9
pubmed: 16882780
Endocrinology. 2012 Jan;153(1):339-49
pubmed: 22128021
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3420-3429
pubmed: 29931354
Nat Commun. 2015 Dec 16;6:10195
pubmed: 26671628
Nat Commun. 2018 Jan 4;9(1):57
pubmed: 29302059
Hum Mol Genet. 2011 Jan 15;20(2):336-44
pubmed: 21059704
Nat Commun. 2018 Oct 10;9(1):4194
pubmed: 30305620
Hum Biol. 1995 Oct;67(5):739-53
pubmed: 8543288
J Clin Endocrinol Metab. 2008 Dec;93(12):4833-9
pubmed: 18812480
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
EMBO Mol Med. 2016 Jun 01;8(6):626-42
pubmed: 27137492
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
N Engl J Med. 2012 Feb 16;366(7):629-35
pubmed: 22335740
J Clin Endocrinol Metab. 2015 Apr;100(4):E646-54
pubmed: 25636053
Nat Neurosci. 2013 Mar;16(3):281-9
pubmed: 23354331
Mol Cell Endocrinol. 2011 Apr 10;336(1-2):117-22
pubmed: 21094676
Cell Physiol Biochem. 2017;43(4):1402-1412
pubmed: 29017168
Endocr Rev. 2003 Oct;24(5):668-93
pubmed: 14570750
Endocrinology. 2006 Mar;147(3):1166-74
pubmed: 16373420
J Clin Endocrinol Metab. 2008 Mar;93(3):723-8
pubmed: 18160460
Pediatrics. 2017 Jun;139(6):null
pubmed: 28562264
Bioinformatics. 2015 Mar 15;31(6):857-63
pubmed: 25391399
N Engl J Med. 1992 Feb 27;326(9):600-4
pubmed: 1734250
J Adolesc. 2003 Oct;26(5):531-45
pubmed: 12972267
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590
J Clin Invest. 2007 Aug;117(8):2145-54
pubmed: 17627301
Trends Endocrinol Metab. 1990 May-Jun;1(5):239-42
pubmed: 18411125
Int J Androl. 2006 Feb;29(1):247-55; discussion 286-90
pubmed: 16466546